Ambulant erworbene Pneumonie bei Erwachsenen

Abstract

Community-acquired pneumonia (CAP) is one of the most common infectious diseases worldwide. To reduce the high morbidity and mortality of CAP, appropriate diagnosis, risk stratification and therapy are necessary. This review summarizes the current recommendations for the management of CAP in Germany. CAP is often a medical emergency. The management of a CAP is based on the individual patient risk. The DS-CRB-65 Score and ATS/IDSA major and minor criteria are well suited for risk stratification. The initially calculated antibiotic therapy is based on the expected spectrum of pathogens and should be adjusted as necessary. Antibiotic therapy is usually administered intravenously in inpatients. With oral therapy, the bioavailability of the antibiotic should be considered. A reevaluation in the first 48–72 hours is mandatory. A therapy duration of 5–7 days is usually sufficient. Preventive influenza and pneumococcal vaccination and nicotine withdrawal are important.

Jeder Verdacht auf eine ambulant erworbene Pneumonie (CAP) muss als ein potenzieller Notfall angesehen werden. Da CAP mit hoher Morbidität und Mortalität einhergeht, ist vor allem in der Erstversorgung bei entsprechendem Verdacht einem Algorithmus zur Diagnosestellung und individualisierten Risikostratifizierung zu folgen. Dieser Beitrag präsentiert aktuelle Empfehlungen zum Management einer CAP.

Schlüsselwörter

Erregerspektrum - Algorithmus - Notfall - Major- und Minor-Kriterien - Bioverfügbarkeit

Key words

pathogen spectrum - algorithm - medical emergency - major and minor criteria - bioavailability

Publication History

Article published online:
19 March 2020

• Literatur

• 1 Kolditz M, Tesch F, Mocke L. et al Burden and risk factors of ambulantory or hospitalized CAP: a population based cohort study. Respir Med 2016; 121: 32-38 . doi:10.1016/j.rmed.2016.10.015
• 2 Pletz MW, Rohde G, Schutte H. et al Epidemiology and aetiology of community-acquired pneumonia (CAP). Dtsch Med Wochenschr 2011; 136: 775-780 . doi:10.1055/s-0031-1275806
• 3 Zhou F, Wang Y, Liu Y. et al Disease severity and clinical outcomes of community-acquired pneumonia caused by non-influenza respiratory viruses in adults: a multicentre prospective registry study from the CAP-China Network. Eur Respir J 2019; 54: 1802406 . doi: 0.1183/13993003.02406-2018
• 4 Moore M, Stuart B, Little P. et al Predictors of pneumonia in lower respiratory tract infections: 3C prospective cough complication cohort study. Eur Respir J 2017; 50: 1700434 . doi:10.1183/13993003.00434-2017
• 5 Claessens YE, Debray MP, Tubach F. et al Early Chest Computed Tomography Scan to Assist Diagnosis and Guide Treatment Decision for Suspected Community-acquired Pneumonia. Am J Resp Crit Care Med 2015; 192: 974-982 . doi:10.1164/rccm.201501-0017OC
• 6 Kolditz M, Ewig S, Schütte H. et al Assessment of oxygenation and comorbidities improves outcome prediction in patients with community-acquired pneumonia with a low CRB-65 score. J Intern Med 2015; 278: 193-202 . doi:10.1111/joim.12349
• 7 Kolditz M, Braeken D, Ewig S. et al Severity Assessment and the Immediate and Long-Term Prognosis in Community-Acquired Pneumonia. Semin Respir Crit Care Med 2016; 37: 886-896 . doi:10.1055/s-0036-1592127
• 8 Metlay JP, Waterer GW, Long AC. et al Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med 2019; 200: e45-e67 . doi:10.1164/rccm.201908-1581ST
• 9 Lepper PM, Ott S, Nüesch E. et al Serum glucose levels for predicting death in patients admitted to hospital for community acquired pneumonia: prospective cohort study. BMJ 2012; 344: e3397 . doi:10.1136/bmj.e3397
• 10 Ewig S, Höffken G, Kern WV. et al S3-Leitlinie: Behandlung von erwachsenen Patienten mit ambulant erworbener Pneumonie und Prävention – Update 2016. Pneumologie 2016; 70: 151-200 . doi: 10.1055/s-0042-101873
• 11 Ferrer R, Martin-Loeches I, Phillips G. et al Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program. Crit Care Med 2014; 42: 1749-1755 . doi:10.1097/CCM.0000000000000330
• 12 Nie W, Li B, Xiu Q. β-Lactam/macrolide dual therapy versus β-lactam monotherapy for the treatment of community-acquired pneumonia in adults: a systematic review and meta-analysis. J Antimicrob Chemother 2014; 69: 1441-1446 . doi:10.1093/jac/dku033
• 13 König R, Cao X, Oswald M. et al Macrolide combination therapy for hospitalised CAP patients? An individualised approach supported by machine learning. Eur Respir J 2019; DOI: 10.1183/13993003.00824-2019.
• 14 Stets R, Popescu M, Gonong JR. et al Omadacycline for Community-Acquired Bacterial Pneumonia. N Engl J Med 2019; 380: 517-527 . doi:10.1056/NEJMoa1800201
• 15 Barrera CM, Mykietiuk A, Metev H. et al Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia (SOLITAIRE-ORAL). Lancet Infect Dis 2016; 16: 421-430 . doi:10.1016/S1473-3099(16)00017-7
• 16 Frat JP, Thille AW, Girault C. et al High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. NEJM 2015; 372: 2185-2196 . doi:10.1056/NEJMoa1503326
• 17 Brack MC, Lienau J, Kuebler WM. et al Cardiovascular sequelae of pneumonia. Curr Opin Pulm Med 2019; 25: 257-262 . doi:10.1097/MCP.0000000000000584
• 18 Schuetz P, Müller B, Christ-Crain M. et al Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. CDS 2017; 10: CD007498 . doi:10.1002/14651858
• 19 Robert Koch Institut. Empfehlungen der Ständigen Impfkommission beim Robert Koch-Institut – 2019/2020, Epidemiologisches Bulletin Nr. 34. Stand: 29.01.2020; 22. August 2019. Im Internet: www.rki.de/DE/Content/Kommissionen/STIKO/Empfehlungen/Impfempfehlungen_node.htm
• 20 Baskaran V, Murray RL, Hunter A. et al Effect of tobacco smoking on the risk of developing community acquired pneumonia: A systematic review and meta-analysis. PLoS One 2019; 14: e0220204 . doi:10.1371/journal.pone.0220204